Clinical Trials Logo

MERS clinical trials

View clinical trials related to MERS.

Filter by:
  • None
  • Page 1

NCT ID: NCT04672577 Not yet recruiting - Influenza Clinical Trials

Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria

ITIT
Start date: January 30, 2021
Phase:
Study type: Observational

The investigators hypothesize that sex, age, area of exposure and purpose of travel are associated with different travel-related infections. The investigators also hypothesize that certain infections will have long-term sequelae. Health-data will be collected from travellers from Switzerland and Europe. The project starts with a pilot study for 50 travellers, followed by the recruiting of 10,000 travellers. The data collection will be via a mobile App (ITIT). The ITIT App will collect active data from travellers. The participants will download the App after signing an electronic consent form and completing a baseline questionnaire. Then the travellers will answer a short daily questionnaire about illness symptoms during travel. The ITIT App will also collect passive data (GPS localisation, environmental and weather data). The project will provide real-time data on travel-related infections and profile travel illness by age, sex and purpose of travel and also identify outbreaks.

NCT ID: NCT04130594 Recruiting - Clinical trials for MERS (Middle East Respiratory Syndrome)

Study of Safety and Immunogenicity of BVRS-GamVac

Start date: November 7, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of adenoviral-based vaccine against MERS - BVRS-GamVac.

NCT ID: NCT04128059 Recruiting - Clinical trials for MERS (Middle East Respiratory Syndrome)

Study of Safety and Immunogenicity of BVRS-GamVac-Combi

Start date: November 6, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of ~34.5%. The aim of the study is to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.